Fig. 6

In vivo pharmacological inhibition of SF3B1 with pladienolide B impairs GBM progression and vascularization. a Generation of a preclinical-xenograft GBM model by inoculation of U-87 MG cells (n = 6). Average tumor volume (b) and weight (c) of intra-tumor pladienolide B injection vs. control-treated tumors. The green arrow in (b) indicates the moment of the corresponding treatment (intra-tumor injection with pladienolide B or control). d Images of each tumor at the moment of sacrifice are shown individually. e 2D- and 3D-micro-CT imaging of a representative preclinical-xenograft GBM -model. f Mitosis number (× 10 HPF; left panel) and representative images of H&E staining (right panel) comparing intratumor pladienolide B injection vs. control-treated tumor samples. g Vascular proliferation evaluation and representative images of H&E staining (left panel) as well as tumor necrosis evaluation and representative images of H&E staining (right panel) of intra-tumor pladienolide B injection vs. control-treated tumor samples. All these evaluations were determined by experienced pathologists. Expression of different tumor progression markers (h) and critical oncogenic spliceosome components (i) after pladienolide B treatment in the preclinical-xenograft GBM model. Asterisks (*P < 0.05; **P < 0.01; ***P < 0.001) indicate statistically significant differences across different conditions